These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 25400440)

  • 21. Resectable pancreatic cancer: is surgery the best first step?
    Russo S; Chabot J; Saif MW
    JOP; 2012 Mar; 13(2):151-4. PubMed ID: 22406588
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Current standards and new innovative approaches for treatment of pancreatic cancer.
    Conroy T; Bachet JB; Ayav A; Huguet F; Lambert A; Caramella C; Maréchal R; Van Laethem JL; Ducreux M
    Eur J Cancer; 2016 Apr; 57():10-22. PubMed ID: 26851397
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Resection of Borderline Resectable and Locally Advanced Pancreatic Adenocarcinomas after Neoadjuvant Chemotherapy.
    Addeo P; Rosso E; Fuchshuber P; Oussoultzoglou E; De Blasi V; Simone G; Belletier C; Dufour P; Bachellier P
    Oncology; 2015; 89(1):37-46. PubMed ID: 25766660
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival.
    Rose JB; Rocha FG; Alseidi A; Biehl T; Moonka R; Ryan JA; Lin B; Picozzi V; Helton S
    Ann Surg Oncol; 2014 May; 21(5):1530-7. PubMed ID: 24473642
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adenocarcinoma of the head of the pancreas: effects of surgical and nonsurgical therapy on survival--a ten-year experience.
    Carr JA; Ajlouni M; Wollner I; Wong D; Velanovich V
    Am Surg; 1999 Dec; 65(12):1143-9. PubMed ID: 10597062
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of radiation therapy in pancreatic ductal adenocarcinoma in the neoadjuvant and adjuvant settings.
    Franke AJ; Rosati LM; Pawlik TM; Kumar R; Herman JM
    Semin Oncol; 2015 Feb; 42(1):144-62. PubMed ID: 25726059
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Radiochemotherapy in the management of pancreatic cancer--part I: neoadjuvant treatment.
    Mornex F; Girard N; Delpero JR; Partensky C
    Semin Radiat Oncol; 2005 Oct; 15(4):226-34. PubMed ID: 16183476
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Implications of Prolonged Time to Pancreaticoduodenectomy After Neoadjuvant Chemoradiation.
    Teng A; Nguyen T; Bilchik AJ; O'Connor V; Lee DY
    J Surg Res; 2020 Jan; 245():51-56. PubMed ID: 31401247
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adjuvant and neoadjuvant treatment for pancreatic adenocarcinoma.
    Motoi F; Unno M
    Jpn J Clin Oncol; 2020 May; 50(5):483-489. PubMed ID: 32083290
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma - A population-based cohort study.
    Labori KJ; Katz MH; Tzeng CW; Bjørnbeth BA; Cvancarova M; Edwin B; Kure EH; Eide TJ; Dueland S; Buanes T; Gladhaug IP
    Acta Oncol; 2016; 55(3):265-77. PubMed ID: 26213211
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neoadjuvant therapy is associated with a reduced lymph node ratio in patients with potentially resectable pancreatic cancer.
    Roland CL; Yang AD; Katz MH; Chatterjee D; Wang H; Lin H; Vauthey JN; Pisters PW; Varadhachary GR; Wolff RA; Crane CH; Lee JE; Fleming JB
    Ann Surg Oncol; 2015 Apr; 22(4):1168-75. PubMed ID: 25352267
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New developments in the management of borderline resectable pancreatic cancer.
    Sharma J; Ng J; Goodman MD; Saif MW
    JOP; 2013 Mar; 14(2):123-5. PubMed ID: 23474551
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of Neoadjuvant Versus Adjuvant Therapy for Resectable Pancreatic Adenocarcinoma: A Decision Analysis.
    Sharma G; Whang EE; Ruan DT; Ito H
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1229-37. PubMed ID: 26152276
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neoadjuvant
    Hashmi A; Kozick Z; Fluck M; Hunsinger MA; Wild J; Arora TK; Shabahang MM; Blansfield JA
    Am Surg; 2018 Sep; 84(9):1439-1445. PubMed ID: 30268172
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Histopathological response to preoperative chemoradiation for resectable pancreatic adenocarcinoma: the French Phase II FFCD 9704-SFRO Trial.
    Le Scodan R; Mornex F; Partensky C; Mercier C; Valette PJ; Ychou M; Roy P; Scoazec JY
    Am J Clin Oncol; 2008 Dec; 31(6):545-52. PubMed ID: 19060585
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neoadjuvant radiation is associated with improved survival in patients with resectable pancreatic cancer: an analysis of data from the surveillance, epidemiology, and end results (SEER) registry.
    Stessin AM; Meyer JE; Sherr DL
    Int J Radiat Oncol Biol Phys; 2008 Nov; 72(4):1128-33. PubMed ID: 18538501
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adjuvant therapy in operable pancreatic cancer.
    Wente MN; Büchler P; Friess H; Büchler MW
    Swiss Surg; 2002; 8(2):74-80. PubMed ID: 12013694
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neoadjuvant therapy of pancreatic cancer: the emerging paradigm?
    Lim KH; Chung E; Khan A; Cao D; Linehan D; Ben-Josef E; Wang-Gillam A
    Oncologist; 2012; 17(2):192-200. PubMed ID: 22250057
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Management of borderline resectable pancreatic adenocarcinoma.
    Jia Y; Wang TJ; Allendorf J; Saif MW
    JOP; 2012 Mar; 13(2):147-50. PubMed ID: 22406587
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neoadjuvant treatment for resectable pancreatic cancer: time for phase III testing?
    Reni M
    World J Gastroenterol; 2010 Oct; 16(39):4883-7. PubMed ID: 20954273
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.